On August 2, 2024, Vice Chancellor for the Office of Research & Creative Activities (ORCA) Roger Wakimoto announced that effective October 1, 2024 overhead rate for industry funded clinical trials will increase from 26% to 33% of total direct costs (TDC). Consistent with the rates of other UC sister campuses, the 7% increase will be used by UCLA to reinvest in infrastructure, improvements in clinical trials administration and support services. The 33% indirect rate will be applicable to new clinical trial contracts executed by the Clinical Trial Contracting & Strategic Relations (CTC-SR) unit with a UCLA IRB application creation date on or after October 1, 2024.
Please reference the table in the BruinPost opens a new window for guidance and applicability of new or legacy industry clinical trial indirect rates. Questions should be sent to your assigned CTC-SR Industry Clinical Trial Contracts Officer or email: clinicaltrials@mednet.ucla.edu(link sends email).
